Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
PLoS One ; 18(3): e0282191, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36888568

RESUMEN

BACKGROUND: Empyema is a life-threatening infection often caused by oral microbiota. To the best of our knowledge, no reports have investigated the association between the objective assessment of oral health and prognosis in patients with empyema. MATERIALS AND METHODS: A total of 63 patients with empyema who required hospitalization at a single institution were included in this retrospective study. We compared non-survivors and survivors to assess risk factors for death at three months, including the Renal, age, pus, infection, diet (RAPID) score, and Oral Health Assessment Tool (OHAT) score. Furthermore, to minimize the background bias of the OHAT high-score and low-score groups determined based on the cut-off value, we also analyzed the association between the OHAT score and death at 3 months using the propensity score matching method. RESULTS: The 3-month mortality rate was 20.6% (13 patients). Multivariate analysis showed that a RAPID score ≥5 points (odds ratio (OR) 8.74) and an OHAT score ≥7 points (OR 13.91) were significantly associated with death at 3 months. In the propensity score analysis, a significant association was found between a high OHAT score (≥7 points) and death at 3 months (P = 0.019). CONCLUSION: Our results indicated that oral health assessed using the OHAT score may be a potential independent prognostic factor in patients with empyema. Similar to the RAPID score, the OHAT score may become an important indicator for the treatment of empyema.


Asunto(s)
Empiema , Salud Bucal , Humanos , Estudios Retrospectivos , Puntaje de Propensión , Pronóstico
2.
Clin Exp Allergy ; 50(8): 932-941, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32542808

RESUMEN

BACKGROUND: Lettuce-associated respiratory allergy has never been reported before. The aim of this study was to clarify the clinical condition of lettuce-associated respiratory allergy and to identify the lettuce antigen which induces allergic symptoms. METHODS: We distributed questionnaires to 1168 lettuce farmers and performed medical examinations in those who exhibited respiratory symptoms related to occupational exposure to lettuce. We analysed specific IgE-binding proteins in the sera of patients through immunoblotting analysis and determined molecular characterization of the IgE-binding bands using liquid chromatography-mass spectrometry. RESULTS: A total of 932 farmers (80%) responded to the questionnaire. Of those, 7% exhibited lettuce-associated respiratory symptoms, during harvesting and packaging. Thirteen patients were diagnosed with allergy to lettuce and agreed to undergo further examinations. The percentage of activated basophils in these patients was significantly higher compared with that reported in negative controls (P < .05). Lettuce-specific IgE (ImmunoCAP® ) and skin prick testing was positive in 46% and 62% of patients, respectively. Notably, occupational lettuce-allergic asthma was detected in one patient through specific bronchial provocation testing. The IgE-binding bands recognized in the sera of >50% of patients were identified as epidermis-specific secreted glycoprotein EP1-like (51 kDa). CONCLUSION: The present analysis identified a novel lettuce allergen. This allergen may have clinically useful applications, such as specific IgE testing and allergen-specific immunotherapy.


Asunto(s)
Enfermedades de los Trabajadores Agrícolas/inmunología , Alérgenos/inmunología , Lactuca/inmunología , Proteínas de Plantas/inmunología , Hipersensibilidad Respiratoria/inmunología , Anciano , Enfermedades de los Trabajadores Agrícolas/sangre , Enfermedades de los Trabajadores Agrícolas/diagnóstico , Biomarcadores/sangre , Pruebas de Provocación Bronquial , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunoglobulina E/sangre , Pruebas Intradérmicas , Japón , Masculino , Persona de Mediana Edad , Exposición Profesional , Salud Laboral , Valor Predictivo de las Pruebas , Hipersensibilidad Respiratoria/sangre , Hipersensibilidad Respiratoria/diagnóstico , Factores de Riesgo
3.
Kobe J Med Sci ; 64(5): E174-E179, 2019 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-30988264

RESUMEN

In developed countries such as North America, the decline in mortality from bronchial asthma has ceased since 2006. The decline in mortality rate is also decreasing in Japan, where about 1,500 asthma deaths have been reported. Among these, elderly people aged 65 years or over account for about 90% of cases. Therefore, the treatment of elderly patients with asthma is an important subject. However, few studies have been conducted on asthma in elderly patients. In this survey, we distributed a questionnaire to 253 elderly care facilities in Kobe, Japan. Ninety facilities responded, and 223 patients in 70 out of 90 facilities were diagnosed with asthma. Dry powder inhaler was the most commonly used dosage form of inhaled corticosteroids. Many facilities have patients who need some assistance during inhalation: only 60% of facilities reported that inhalation is performed accurately. While 31 facilities had patients with a history of hospitalization for asthma attacks, only 14 of these facilities were able to provide appropriate initial treatment. Many facilities have difficulty providing assistance with inhalation to elderly patients whose cognitive function has deteriorated. This survey highlights challenges experienced by care facilities in treating asthma in the elderly.


Asunto(s)
Asma/diagnóstico , Asma/terapia , Hogares para Ancianos , Casas de Salud , Encuestas y Cuestionarios , Administración por Inhalación , Corticoesteroides/administración & dosificación , Anciano , Asma/epidemiología , Encuestas de Atención de la Salud , Humanos , Japón/epidemiología
4.
Intern Med ; 56(24): 3333-3339, 2017 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-29021485

RESUMEN

A 20-year-old Japanese woman with a history of pulmonary atresia was referred to our hospital after the detection of an abnormal mass in the right lung and mediastinal lymphadenopathy. A cytological specimen obtained by transbronchial brushing indicated that the pathological diagnosis was non-small cell lung cancer. During the follow-up period, the tumor spontaneously regressed. At four months after the diagnosis, she experienced sudden bleeding from the small intestine. The histological characteristics of the small intestine tumor were compatible with the cytological characteristics of the lung tumor. Detailed immunohistochemical analyses led to a final diagnosis of epithelial angiosarcoma of the small intestine, which might have formed metastatic lesions in the lung.


Asunto(s)
Hemangiosarcoma/patología , Hemangiosarcoma/secundario , Neoplasias Intestinales/patología , Neoplasias Pulmonares/secundario , Regresión Neoplásica Espontánea , Femenino , Hemangiosarcoma/diagnóstico , Humanos , Intestino Delgado/patología , Neoplasias Pulmonares/patología , Adulto Joven
5.
Jpn J Clin Oncol ; 44(8): 762-4, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24872405

RESUMEN

We report the case of a 70-year-old Japanese male diagnosed with advanced lung adenocarcinoma harboring the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene. As soon as crizotinib was administered, tumor shrank immediately. On Day 25, he developed interstitial lung disease. Bronchoalveolar lavage fluid analysis demonstrated elevated lymphocytes fractionation. A drug lymphocyte stimulating test for crizotinib with the bronchoalveolar lavage lymphocytes was negative. Crizotinib administration was discontinued, but a life-threatening flare of tumor growth occurred. Since there was no alternative treatment for the lung cancer, we restarted crizotinib in combination with prednisolone. The patient experienced neither disease progression nor recurrence of interstitial lung disease at 6 months. In cases in which no alternate treatment is known, crizotinib retreatment combined with steroid therapy after crizotinib-induced interstitial lung disease could be considered after a careful consideration of the potential risks and benefits.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Enfermedades Pulmonares Intersticiales/inducido químicamente , Neoplasias Pulmonares/tratamiento farmacológico , Pirazoles/efectos adversos , Pirazoles/uso terapéutico , Piridinas/efectos adversos , Piridinas/uso terapéutico , Anciano , Antineoplásicos Hormonales/uso terapéutico , Líquido del Lavado Bronquioalveolar/citología , Broncoscopía , Crizotinib , Quimioterapia Combinada , Humanos , Linfocitos/citología , Masculino , Prednisolona/uso terapéutico , Inhibidores de Proteínas Quinasas/efectos adversos , Inhibidores de Proteínas Quinasas/uso terapéutico , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
6.
Arerugi ; 63(1): 52-60, 2014 Feb.
Artículo en Japonés | MEDLINE | ID: mdl-24647423

RESUMEN

OBJECTIVE: To elucidate the actual condition of asthma treatment in emergency settings. METHODS: A questionnaire survey on the situation of emergency care was conducted on 175 medical institutions providing either secondary or tertiary emergency care in Hyogo Prefecture during a 1-year period starting in April 2010. Data were investigated for each secondary medical region. RESULTS: Responses were obtained from 143 medical institutions (response rate, 81.7%). Steroid injection, aminophylline injection, and short-acting beta-agonists (SABA) were selected as drugs in emergency room treatment in many districts (in order, means of 86.7%, 79.5%, 72.3%). Concerning drugs prescribed on leaving hospital, transdermal ß2 stimulator and SABA were selected in >50% of districts. Prescriptions for long-term management varied among districts, as follows: inhaled corticosteroids (ICS), mean of 37.3% (0-66.7%); ICS/long-acting ß-agonists (LABA), 27.9% (16.7-66.7%); and leukotriene receptor antagonist (LTRA), 20.5% (0-50.0%) CONCLUSION: These findings suggest that asthma treatment in emergency settings varies by facility and region.


Asunto(s)
Comités Consultivos/organización & administración , Asma/tratamiento farmacológico , Asma/mortalidad , Servicio de Urgencia en Hospital , Servicios Preventivos de Salud/organización & administración , Encuestas y Cuestionarios , Adolescente , Corticoesteroides/administración & dosificación , Agonistas Adrenérgicos beta/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Aminofilina/administración & dosificación , Asma/epidemiología , Broncodilatadores/administración & dosificación , Niño , Preescolar , Quimioterapia , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Humanos , Lactante , Japón/epidemiología , Antagonistas de Leucotrieno/administración & dosificación , Masculino , Persona de Mediana Edad
7.
Intern Med ; 50(24): 3019-22, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22185996

RESUMEN

The present study describes a case of a 60-year-old Japanese man who was histologically diagnosed with lung adenocarcinoma harboring L858R mutation of epidermal growth factor receptor. He was successfully treated with gefitinib, but eventually developed leptomeningeal carcinomatosis. He underwent ventriculoperitoneal shunting for hydrocephalus and received erlotinib in place of gefitinib with concurrent whole brain radiotherapy; this resulted in dramatic improvement in his symptoms and performance status from four to one and he survived for as long as 13.6 months after the initiation of erlotinib therapy. This multidisciplinary approach may be particularly useful in terms of increasing survival and improving quality of life.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/terapia , Neoplasias Pulmonares/terapia , Carcinomatosis Meníngea/secundario , Carcinomatosis Meníngea/terapia , Carcinoma de Pulmón de Células no Pequeñas/genética , Terapia Combinada , Receptores ErbB/genética , Clorhidrato de Erlotinib , Gefitinib , Humanos , Neoplasias Pulmonares/genética , Masculino , Carcinomatosis Meníngea/genética , Persona de Mediana Edad , Mutación , Quinazolinas/uso terapéutico , Radioterapia Adyuvante , Factores de Tiempo , Resultado del Tratamiento , Derivación Ventriculoperitoneal
8.
Lung Cancer ; 74(2): 284-92, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21411176

RESUMEN

Lung cancer is one of the most common cancers in the world, but no good clinical markers that can be used to diagnose the disease at an early stage and predict its prognosis have been found. Therefore, the discovery of novel clinical markers is required. In this study, metabolomic analysis of lung cancer patients was performed using gas chromatography mass spectrometry. Serum samples from 29 healthy volunteers and 33 lung cancer patients with adenocarcinoma (n=12), squamous cell carcinoma (n=11), or small cell carcinoma (n=10) ranging from stage I to stage IV disease and lung tissue samples from 7 lung cancer patients including the tumor tissue and its surrounding normal tissue were used. A total of 58 metabolites (57 individual metabolites) were detected in serum, and 71 metabolites were detected in the lung tissue. The levels of 23 of the 58 serum metabolites were significantly changed in all lung cancer patients compared with healthy volunteers, and the levels of 48 of the 71 metabolites were significantly changed in the tumor tissue compared with the non-tumor tissue. Partial least squares discriminant analysis, which is a form of multiple classification analysis, was performed using the serum sample data, and metabolites that had characteristic alterations in each histological subtype and disease stage were determined. Our results demonstrate that changes in metabolite pattern are useful for assessing the clinical characteristics of lung cancer. Our results will hopefully lead to the establishment of novel diagnostic tools.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Neoplasias Pulmonares/diagnóstico , Pulmón/metabolismo , Suero/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Pulmón de Células no Pequeñas/fisiopatología , Detección Precoz del Cáncer , Estudios de Factibilidad , Femenino , Cromatografía de Gases y Espectrometría de Masas , Humanos , Pulmón/patología , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/fisiopatología , Masculino , Metabolómica/métodos , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Fumar , Adulto Joven
9.
Case Rep Pulmonol ; 2011: 812972, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22937431

RESUMEN

A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuation of gefitinib. Gefitinib was reintroduced with an intermittent treatment schedule after the transaminase levels normalized, but the patient's enzyme levels rose again, and the cancer progressed. Gefitinib was eventually replaced with erlotinib. There was stable disease for 7 weeks without any signs of liver toxicity. Thus, erlotinib may be a beneficial and well-tolerated treatment option for patients with gefitinib-related hepatotoxicity.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...